Drug Trial Radar · NCT05909397
Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer
Last checked: Nov 19, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
59
Actual
Start
Aug 9, 2023
Primary completion
Dec 30, 2026
Study completion Dec 30, 2026
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- Arvinas Estrogen Receptor, Inc.
- First posted
- Jun 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to understand the safety and effects of the study medicine vepdegestrant (ARV-471/PF-07850327) given together with palbociclib in advanced breast cancer. In particular, the study will compare the combination of vepdegestrant plus palbociclib to standard of care therapy (letrozole plus palbociclib). Both letrozole and palbociclib are medicines already used for treatment of breast cancer. Vepdegestrant is a new medicine under study. This study is seeking participants who have breast cancer that: * Have a locally advanced or metastatic disease and cannot be fully cured by surgery or radiation therapy. A metastatic disease is when disease has spread to other parts of the body. * Is sensitive to hormonal therapy such as tamoxifen. This is called estrogen receptor positive disease. * Have not received any prior medicine for advanced disease. Example medications include tamoxifen or letrozole or exemestane. The study will have an open-label SLI (study lead-in) before initiation of Phase 3 trial. During SLI, two dose levels of palbociclib in combination with vepdegestrant will be explored in parallel. Assignment to the palbociclib dose is by chance. Half of the participant will receive one dose and the other half another palbociclib dose. The purpose of SLI is to determine the recommended Phase 3 dose of palbociclib to be administered in combination with vepdegestrant. In the Phase 3, half of the participants will take vepdegestrant plus palbociclib while the other half will take letrozole plus palbociclib. In both SLI and Phase 3, participants will take the study medicines by mouth, with food, once a day. Participants will take the study medicines until breast cancer increase in size or side effects become too severe. Side effects refer to unwanted reactions to medications. Participants will visit the study clinic about once every 4 weeks.
Conditions
- Breast Cancer
Interventions
Vepdegestrant (ARV-471/PF-07850327)Drug
Pharmaceutical form: Tablets. Route of Administration: Oral
PalbociclibCombination product
Pharmaceutical form: Capsules. Route of Administration: Oral.
LetrozoleDrug
Pharmaceutical form: Capsules. Route of Administration: Orally
PalbociclibCombination product
Pharmaceutical form: Capsules. Route of Administration: Oral.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Study Lead-in (SLI): Incidence of Grade 4 neutropeniaTime frame: From randomization date up to Cycle 4 (each cycle is 28 days).
- SLI: Incidence of dose reductionTime frame: From randomization date up to Cycle 4 (each cycle is 28 days).
- SLI: Incidence of drug discontinuation.Time frame: From randomization date up to Cycle 4 (each cycle is 28 days).
- Phase 3: Progression-Free SurvivalTime frame: From randomization date, every 12 weeks, to date of first documentation of progression or death, up to approximately 4 years.
Locations
29 sites in 10 countries. Site status is shown where the registry gives one.
BRCR Global
Plantation, Florida
BRCR Medical Center Inc
Plantation, Florida
Virginia Oncology Associates
Norfolk, Virginia
Cancer Research SA
Adelaide, South Australia, Australia
Barwon Health
Geelong, Victoria, Australia
Hospital Santa Rita de Cassia
Vitória, Espírito Santo, Brazil
Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa
Porto Alegre, Rio Grande do Sul, Brazil
Centro de Pesquisa Clínica - Área Administrativa
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Mae de Deus
Porto Alegre, Rio Grande do Sul, Brazil
Cancer Hospital Chinese Academy of Medical Science
Beijing, Beijing Municipality, China
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Hubei Cancer Hospital
Wuhan, Hubei, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China
Debreceni Egyetem Klinikai Kozpont
Debrecen, Hungary
Istituto Nazionale Tumori IRCCS Fondazione Pascale
Naples, Campania, Italy
IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"
Meldola, Emilia-Romagna, Italy
Fondazione IRCCS San Gerardo dei Tintori
Monza, Lombardy, Italy
Aichi Cancer Center Hospital
Nagoya, Aichi-ken, Japan
National Cancer Center Hospital East
Kashiwa, Chiba, Japan
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
Nemocnica na okraji mesta n o
Partizánske, Slovakia
Fakultna nemocnica s poliklinikou J.A. Reimana Presov
Prešov, Slovakia
Hospital Unviersitario Virgen Nieves
Granada, Spain
Hospital Clinico San Carlos
Madrid, Spain
Institut Català d'Oncologia (ICO) - Badalona
Badalona, Barcelona [barcelona], Spain
Hospital Universitari Dexeus
Barcelona, Catalunya [cataluña], Spain
Complejo Hospitalario de Jaén
Jaén, JAÉN, Spain
Hospital Universitario Virgen de la Victoria
Málaga, Málaga, Spain
Tumor Zentrum Aarau
Aarau, Canton of Aargau, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.